GO:2001141 regulation of RNA biosynthetic process: Transcription Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001141 regulation of RNA biosynthetic process describes any process that modulates the frequency, rate or extent of RNA biosynthesis, encompassing both transcriptional and co-transcriptional control points.
• The term is a biological_process node that sits upstream of RNA polymerase-driven transcription and integrates signals from nucleotide metabolism, RNA modifications and splicing regulators.
• Key regulatory layers include RNA polymerase II recruitment, elongation control, m6A-dependent RNA modification and alternative splicing of immune effectors such as MyD88.
• Dysregulation of RNA biosynthetic process regulation is linked to cancer, atherosclerosis, skeletal muscle disorders and innate immune pathologies.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the primary tools for dissecting causal roles of regulators in this process.
• Antisense oligonucleotides and small-molecule splicing modulators demonstrate that therapeutic modulation of RNA biosynthesis regulation is clinically actionable.
Description
GO:2001141 regulation of RNA biosynthetic process is a Gene Ontology biological_process term defined as any process that modulates the frequency, rate or extent of RNA biosynthetic process. It captures the regulatory inputs that determine when, where and how much RNA is synthesized, spanning transcriptional initiation, elongation and co-transcriptional events that influence RNA output. Because RNA biosynthesis is the first step in gene expression, its regulation is central to cellular responses to nutrients, stress and immune signals. Researchers study this term to understand how cells allocate biosynthetic capacity, how nucleotide metabolism is coupled to RNA production, and how RNA modifications feed back on transcription. The term is distinct from the biosynthetic process itself; it specifically denotes the modulatory processes that set the frequency, rate or extent of RNA synthesis. In practice, GO:2001141 is used to annotate gene products that control RNA polymerase activity, chromatin accessibility, elongation factor recruitment and co-transcriptional RNA processing. Its relevance extends to disease: altered regulation of RNA biosynthesis underlies cancer cell proliferation, atherosclerosis-associated cell states and innate immune imbalance. This article synthesizes authoritative QuickGO annotation logic with verified PubMed literature to provide a research-grade overview of GO:2001141, its mechanisms, key genes, disease links and experimental models.
regulation of RNA biosynthetic process At A Glance
| GO ID | GO:2001141 |
|---|---|
| GO term | regulation of RNA biosynthetic process |
| Ontology | biological_process |
| Definition | Any process that modulates the frequency, rate or extent of RNA biosynthetic process. |
| Synonyms | regulation of RNA anabolism; regulation of RNA biosynthesis; regulation of RNA formation; regulation of RNA synthesis |
| Major function | Controls the frequency, rate and extent of RNA synthesis, integrating transcriptional and co-transcriptional regulatory inputs. |
| Related processes | Nucleotide metabolism, RNA modification, alternative splicing and innate immune signaling. |
| Disease relevance | Cancer, atherosclerosis, skeletal muscle disorders and immune dysregulation. |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, m6A profiling, splicing assays. |
What Is GO:2001141?
In plain terms, GO:2001141 regulation of RNA biosynthetic process refers to any cellular process that changes how often, how fast or how extensively RNA is made. The QuickGO definition states: Any process that modulates the frequency, rate or extent of RNA biosynthetic process. This places the term as a regulatory parent that governs RNA synthesis without being the synthesis reaction itself. It includes signals that activate or repress RNA polymerase recruitment, elongation and co-transcriptional maturation events that determine net RNA output.
Why Is regulation of RNA biosynthetic process Important in Cell Biology?
GO:2001141 regulation of RNA biosynthetic process is important because RNA biosynthesis is the rate-limiting step for gene expression and is tightly coupled to nucleotide availability, epigenetic state and RNA modification status. Perturbations in this regulatory layer alter cell fate, proliferation and immune responses, making it a focal point for cancer, metabolic and inflammatory disease research. Understanding it also informs therapeutic strategies such as antisense oligonucleotides and splicing modulators that act on RNA biosynthetic outputs.
• Sets the frequency and rate of RNA synthesis, directly influencing gene expression output.
• Couples nucleotide metabolism to RNA production, linking metabolic state to biosynthetic capacity.
• Integrates RNA modifications such as m6A into co-transcriptional regulation.
• Controls alternative splicing of immune effectors like MyD88, limiting innate immune responses.
• Dysregulation is implicated in atherosclerosis-associated cell states.
• Altered regulation contributes to skeletal muscle developmental disorders.
• Provides mechanistic basis for antisense oligonucleotide drug action.
• Informs small-molecule splicing modulation such as risdiplam.
• Enables CRISPR-based causal dissection of regulatory nodes.
• Supports biomarker and therapeutic target discovery in cancer and inflammation.
What Happens During regulation of RNA biosynthetic process?
Initiation control at RNA polymerase recruitment
In simple terms: This step decides whether the RNA-making machine is allowed to start.
Regulation of RNA biosynthetic process begins with control of RNA polymerase recruitment to gene promoters, which sets the frequency of transcription initiation. Signals from nucleotide metabolism and chromatin state influence whether RNA polymerase is poised or active, thereby modulating the rate of RNA synthesis. Co-transcriptional RNA modifications can further feed back on initiation efficiency.
Elongation and co-transcriptional RNA modification
In simple terms: Once started, the RNA-making machine can be sped up or slowed down, and the new RNA can be chemically tagged.
Elongation control determines the extent of RNA synthesis after initiation, and RNA modifications such as m6A are deposited co-transcriptionally to modulate RNA fate. m6A modification is dynamically regulated and affects RNA stability and translation, indirectly influencing net RNA biosynthetic output. In atherosclerosis, cell-type-specific m6A patterns reveal functional roles in regulating RNA metabolism.
Alternative splicing as a co-transcriptional regulatory layer
In simple terms: The newly made RNA can be cut and pasted in different ways, changing the final message.
Alternative splicing occurs co-transcriptionally and is a key component of RNA biosynthetic process regulation. SF3A-dependent control of MyD88 alternative mRNA splicing limits innate immune responses, demonstrating that splicing regulators modulate the functional output of RNA biosynthesis. This layer connects GO:2001141 to immune homeostasis.
Nucleotide metabolism and biosynthetic capacity
In simple terms: Making RNA requires building blocks, and the cell adjusts production based on supply.
Regulation of mammalian nucleotide metabolism and biosynthesis directly impacts the availability of substrates for RNA synthesis. Cells coordinate nucleotide supply with RNA biosynthetic demand, and this coupling is part of the regulatory logic of GO:2001141. Disruption of this balance can alter the rate and extent of RNA production.
Therapeutic modulation of RNA biosynthetic regulation
In simple terms: Drugs can tweak the RNA-making process to treat disease.
Antisense oligonucleotide drugs modulate RNA biosynthetic outputs by altering splicing or degrading specific transcripts. Risdiplam, a small-molecule splicing modulator, exemplifies therapeutic regulation of RNA biosynthetic process for spinal muscular atrophy. These examples show that GO:2001141 is druggable at multiple regulatory nodes.
Key Genes Involved in GO:2001141 regulation of RNA biosynthetic process
The following genes and proteins are experimentally implicated in regulating RNA biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SF3A1 | Splicing factor 3a subunit 1; controls MyD88 alternative splicing | Innate immune response limitation |
| MYD88 | Adaptor in innate immune signaling; its splicing is regulated by SF3A | Immune homeostasis |
| METTL3 | m6A methyltransferase; deposits co-transcriptional RNA modification | RNA modification and skeletal muscle development |
| METTL14 | m6A methyltransferase complex component | RNA modification studies |
| WTAP | m6A methyltransferase complex regulatory subunit | Epigenome regulation |
| FTO | m6A demethylase; removes RNA methylation | RNA modification dynamics |
| ALKBH5 | m6A demethylase | Epigenome regulation |
| YTHDF1 | m6A reader; affects RNA fate | RNA stability and translation |
| YTHDF2 | m6A reader; affects RNA stability | RNA modification studies |
| IGF2BP1 | m6A reader; modulates RNA stability | Skeletal muscle development |
| POLR2A | RNA polymerase II largest subunit; core enzyme for RNA synthesis | Transcription regulation |
| CDK9 | Cyclin-dependent kinase 9; regulates elongation | Transcriptional control |
| BRD4 | Bromodomain protein; couples chromatin to transcription | Epigenome regulation |
| SMN1 | Survival motor neuron 1; splicing modulator target | Spinal muscular atrophy |
| SMN2 | Survival motor neuron 2; risdiplam target for splicing correction | Spinal muscular atrophy therapy |
| DNMT1 | DNA methyltransferase; influences chromatin and RNA output | Epigenome regulation |
| HDAC1 | Histone deacetylase; modulates chromatin accessibility | Epigenome regulation |
| EIF4E | Translation initiation factor; indirectly linked to RNA metabolism | Nucleotide metabolism coupling |
How Is regulation of RNA biosynthetic process Regulated?
Regulation of RNA biosynthetic process is itself controlled by upstream signals including nutrient availability, nucleotide metabolism and RNA modification feedback. m6A modification dynamically regulates RNA fate and can feed back on transcription. In innate immunity, SF3A-dependent splicing control of MyD88 limits immune responses, showing that splicing regulators act as upstream modulators of RNA biosynthetic output. Therapeutic agents such as antisense oligonucleotides and risdiplam further demonstrate that this regulatory layer can be pharmacologically tuned.
regulation of RNA biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Skeletal muscle development and cancer | Knockout and overexpression in muscle cell lines |
| FTO | RNA modification dynamics in disease | Point-mutation models of demethylase activity |
| SF3A1 | Innate immune dysregulation | Knockout in macrophage cell lines |
| MYD88 | Inflammation and immune signaling | Knock-in of splicing isoforms |
| SMN2 | Spinal muscular atrophy | Splicing modulator treatment models |
Cancer and proliferative signaling
Dysregulated RNA biosynthetic process regulation supports cancer cell proliferation by increasing RNA output and altering co-transcriptional RNA modification. m6A modification patterns are cell-type-specific and contribute to disease-relevant cell states. Targeting regulatory nodes in RNA biosynthesis is an active therapeutic strategy.
Atherosclerosis and vascular disease
Single-cell landscape studies reveal cell-type-specific functional roles of RNA m6A modification in atherosclerosis, linking RNA biosynthetic regulation to vascular pathology. These findings position GO:2001141 regulators as potential disease modifiers.
Skeletal muscle disorders
Regulation of RNA N6-methyladenosine modification has emerging roles in skeletal muscle development, and its disruption is associated with muscle disorders. m6A writers, erasers and readers modulate RNA biosynthetic outputs in muscle cells.
Innate immune dysregulation
SF3A-dependent control of MyD88 alternative mRNA splicing limits innate immune responses, and loss of this regulation can lead to immune imbalance. This connects RNA biosynthetic process regulation to inflammatory disease.
From regulation of RNA biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate regulator causally required for RNA synthesis? | CRISPR knockout cell line |
| Does a specific amino acid change alter regulatory activity? | CRISPR point-mutation knock-in |
| Does tagging the endogenous protein affect its function? | Tagged knock-in |
| Does overexpression drive RNA biosynthetic output? | CRISPR overexpression model |
| Which regulatory nodes are essential in disease cells? | CRISPR library screening |
| How does m6A modification affect RNA fate? | m6A profiling with knockout/overexpression |
How to Study the regulation of RNA biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Steady-state RNA levels and splicing | Transcriptome-wide effects of perturbations |
| MeRIP-seq | m6A modification sites | Mapping RNA methylation dynamics |
| Splicing assay | Alternative mRNA isoforms | MyD88 splicing regulation |
| CRISPR knockout | Loss-of-function effects | Causal gene discovery |
| CRISPR point mutation | Specific amino acid function | Dissecting catalytic residues |
| CRISPR knock-in | Tagged or mutant allele function | Endogenous protein tracking |
| CRISPR overexpression | Gain-of-function effects | Testing sufficiency |
| CRISPR library screening | Pooled gene function | Unbiased regulator discovery |
RNA-seq and transcriptome profiling
RNA-seq measures steady-state RNA levels and splicing changes to assess the output of RNA biosynthetic process regulation. It is widely used to quantify effects of CRISPR perturbations on RNA synthesis.
m6A modification profiling
m6A-specific methods such as MeRIP-seq map RNA methylation sites and quantify dynamic changes in co-transcriptional modification. These approaches link RNA modification to RNA biosynthetic regulation.
Splicing assays
Splicing assays detect alternative mRNA isoforms, such as MyD88 variants regulated by SF3A. They are essential for studying co-transcriptional regulatory layers.
CRISPR screening and functional genomics
CRISPR library screening identifies genes that modulate RNA biosynthetic process under specific conditions. This method enables unbiased discovery of regulatory nodes.
How CRISPR Can Be Used to Study GO:2001141 regulation of RNA biosynthetic process
Knockout
CRISPR knockout creates loss-of-function alleles to test whether a candidate regulator is required for RNA biosynthetic process. This is the primary approach for causal gene discovery in GO:2001141 research.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to dissect catalytic or regulatory domains without altering protein abundance. It is used to test whether enzymatic activity of m6A writers or erasers is required.
Knock-in
CRISPR knock-in enables tagging or replacement of endogenous alleles to track protein localization and function in RNA biosynthetic regulation. Tagged knock-in models are valuable for imaging and interaction studies.
Overexpression
CRISPR overexpression tests sufficiency of a regulator to drive RNA biosynthetic output. It complements knockout studies by revealing gain-of-function phenotypes.
How EDITGENE Supports regulation of RNA biosynthetic process Research
Researchers studying regulation of RNA biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in RNA synthesis, RNA modification or splicing control. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of RNA biosynthetic process research.
Frequently Asked Questions About regulation of RNA biosynthetic process
What is GO:2001141 regulation of RNA biosynthetic process?
GO:2001141 is a Gene Ontology biological_process term defined as any process that modulates the frequency, rate or extent of RNA biosynthetic process.
What genes are involved in regulation of RNA biosynthetic process?
Genes include METTL3, METTL14, WTAP, FTO, ALKBH5, YTHDF1, YTHDF2, SF3A1, MYD88, POLR2A, CDK9 and BRD4, among others.
How is RNA biosynthetic process regulated?
It is regulated at initiation, elongation and co-transcriptional RNA modification and splicing steps, coupled to nucleotide metabolism.
What diseases are linked to regulation of RNA biosynthetic process?
Cancer, atherosclerosis, skeletal muscle disorders and innate immune dysregulation have been linked to altered regulation.
What is the role of m6A in RNA biosynthetic process regulation?
m6A is a co-transcriptional RNA modification that dynamically regulates RNA fate and feeds back on RNA biosynthetic output.
How do CRISPR models help study GO:2001141?
CRISPR knockout, point mutation, knock-in and overexpression models enable causal testing of regulatory genes.
What methods measure RNA biosynthetic process regulation?
RNA-seq, MeRIP-seq, splicing assays and CRISPR screening are commonly used.
Is regulation of RNA biosynthetic process druggable?
Yes, antisense oligonucleotides and splicing modulators such as risdiplam demonstrate therapeutic modulation.
What is the difference between RNA biosynthetic process and its regulation?
RNA biosynthetic process is the synthesis itself, while GO:2001141 describes processes that modulate its frequency, rate or extent.
Which cell models are suitable for GO:2001141 research?
Knockout, point-mutation, knock-in, tagged knock-in and overexpression cell models are suitable.
Conclusion
GO:2001141 regulation of RNA biosynthetic process is a central biological_process term that captures how cells control the frequency, rate and extent of RNA synthesis through transcriptional, co-transcriptional and metabolic inputs. Its dysregulation is linked to cancer, atherosclerosis, skeletal muscle disorders and immune imbalance, making it a high-value target for mechanistic and therapeutic research. CRISPR-based cell models, combined with RNA-seq, m6A profiling and splicing assays, provide the experimental toolkit to dissect this regulatory layer. EDITGENE supports these efforts with comprehensive knockout, point-mutation, knock-in, overexpression and library screening services.
References
- 1. Lane AN et al.. 2015. Regulation of mammalian nucleotide metabolism and biosynthesis.. Nucleic Acids Res 43(4):2466-85 PMID: 25628363
- 2. Shinwari ZK et al.. 2018. Ethical Issues Regarding CRISPR Mediated Genome Editing.. Curr Issues Mol Biol 26:103-110 PMID: 28879860
- 3. Patrasso EA et al.. 2023. Regulation of the epigenome through RNA modifications.. Chromosoma 132(3):231-246 PMID: 37138119
- 4. Sang A et al.. 2024. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.. BioDrugs 38(4):511-526 PMID: 38914784
- 5. Ping X et al.. 2025. Deciphering single-cell landscape unravels cell-type-specific functional roles of RNA m(6)A modification in atherosclerosis.. Theranostics 15(10):4785-4807 PMID: 40225569
- 6. Dhillon S. 2020. Risdiplam: First Approval.. Drugs 80(17):1853-1858 PMID: 33044711
- 7. Li J et al.. 2021. Regulation of RNA N(6)-methyladenosine modification and its emerging roles in skeletal muscle development.. Int J Biol Sci 17(7):1682-1692 PMID: 33994853
- 8. De Arras L et al.. 2013. Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing.. PLoS Genet 9(10):e1003855 PMID: 24204290
